Jeito Capital, INKEF Capital and Forbion have co-led a EUR 80m Series B for Precirix, a Belgian biotech developing precision radiopharmaceuticals.
Jeito Capital, INKEF Capital and Forbion have co-led a EUR 80m Series B for Precirix, a Belgian biotech developing precision radiopharmaceuticals.